Roche’s etrolizumab missed primary endpoints in its Phase III study program evaluating it as maintenance therapy in moderately to severely active ulcerative colitis, a new therapeutic area for the firm.

New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.

Sandoz and Civica Rx have entered into a long-term collaboration to help mitigate medicine shortages in US hospitals, where Sandoz will supply six critical injectables and Civica will ensure reliable supply of these medicines to patients.

With COVID-19 cases about to top 12 million worldwide, efforts are continuing to identify the most promising drug candidates and to ensure that the rising star dexamethasone is made available to all.